Recent studies have centered on the convergence of GLP|GIP|GCGR stimulant therapies and dopamine communication. While GIP stimulators are commonly employed for addressing type 2 T2DM, their emerging consequences on reward circuits, specifically influenced by dopaminergic pathways, are gaining considerable attention. This paper provides a concise as